Abstract PD1-10: Randomized phase II study comparing two different schedules of palbociclib plus second line endocrine therapy in women with estrogen receptor positive, HER2 negative advanced/metastatic breast cancer: CCTG MA38 (NCT02630693) Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Parulekar, WR
  • Joy, AA
  • Gelmon, K
  • Mates, M
  • Desbiens, C
  • Clemons, M
  • Taylor, S
  • Lemieux, J
  • Bartlett, J
  • Whelan, Timothy
  • Ayoub, J-P
  • Cescon, D
  • Bordeleau, Louise
  • Rahim, Y
  • Winch, C
  • Chen, BE

publication date

  • February 15, 2019